Centre de Regulació Genómica, Barcelona, Spain.
EMBO J. 2010 Dec 1;29(23):3893-5. doi: 10.1038/emboj.2010.281.
Histone deacetylases (HDACs) are attractive chemotherapy targets, owing to their pro-proliferative activities. However, the finding that loss of HDAC1 promotes teratoma malignancy calls for caution in the use of HDAC inhibitors as cancer therapeutics.
组蛋白去乙酰化酶(HDACs)由于其促有丝分裂活性,是有吸引力的化疗靶标。然而,HDAC1 的缺失会促进畸胎瘤恶性转化,这一发现提醒人们在将 HDAC 抑制剂作为癌症治疗药物使用时需谨慎。